Baudax Bio, Inc.
BXRX · NASDAQ
9/30/2023 | 6/30/2023 | 3/31/2023 | 12/31/2022 | |
|---|---|---|---|---|
| Market Cap | $3 | $6 | $4 | $5 |
| - Cash | $0 | $1 | $4 | $5 |
| + Debt | $8 | $9 | $7 | $7 |
| Enterprise Value | $11 | $13 | $8 | $7 |
| Revenue | $0 | $0 | -$0 | $0 |
| % Growth | -100% | 314.3% | -104.5% | – |
| Gross Profit | -$0 | -$0 | -$0 | -$4 |
| % Margin | – | -246.7% | 2,992.9% | -1,445.8% |
| EBITDA | -$0 | -$0 | -$24 | -$7 |
| % Margin | – | -246.7% | 169,150% | -2,157.7% |
| Net Income | -$2 | -$7 | $11 | -$9 |
| % Margin | – | -24,583.3% | -81,457.1% | -2,983.5% |
| EPS Diluted | -0.24 | -1.51 | 4.91 | -5.7 |
| % Growth | 84.1% | -130.8% | 186.1% | – |
| Operating Cash Flow | -$2 | -$3 | -$5 | -$4 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$2 | -$3 | -$5 | -$4 |